



AGILENT TECHNOLOGIES

BARCLAYS CAPITAL 2011 GLOBAL
HEALTHCARE CONFERENCE

MARCH 16, 2011

MIAMI, FLORIDA



AGILENT TECHNOLOGIES

BARCLAYS CAPITAL 2011 GLOBAL
HEALTHCARE CONFERENCE

SOLANGE GLAIZE
OPERATIONAL CFO
LIFE SCIENCES GROUP (LSG)

This presentation contains forward-looking statements (including, without limitation, information and future guidance on our goals, priorities, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earnings, the continued strengths and expected growth of the markets we sell into, operations, operating earnings, and tax rates) that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended January 31, 2011.

The company assumes no obligation to update the information in these presentations. These presentations and the Q&A that follows include non-GAAP numbers. A presentation of the most directly comparable GAAP numbers and the reconciliations between the non-GAAP and GAAP numbers can be found at <http://www.investor.agilent.com> under "Financial Results" and accompany this slide set.

THE WORLD'S PREMIER MEASUREMENT COMPANY

Electronic Measurement Group



FY10 Revenue: \$2.8B
FY10 Operating Margin* 16%

Ron Nersesian
President

Chemical Analysis Group



FY10 Revenue: \$1.2B
FY10 Operating Margin* 23%

Mike McMullen
President

Life Sciences Group



FY10 Revenue: \$1.5B
FY10 Operating Margin* 15%

Nick Roelofs
President

FY10 Revenue \$5.5B, +19% organic growth Y/Y, 17% Operating Margin*
FY10 Non-GAAP EPS \$2.00*. Up from \$0.80* in FY09

*Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided

FY10/11 FINANCIAL HIGHLIGHTS

	FY10	Q1 FY11	FY11 Guidance** (Mid-Point)
Revenue*	\$5.46B	\$1.52B	\$6.35B
Organic Revenue Growth*	19%	19%	12%
Operating Margin*	17.1%	17.7%	18.4%
EPS*	\$2.00	\$0.60	\$2.58
ROIC*	21%	21%	22%
Operating Cash Flow	\$718M	\$120M	\$950M

*Presented on a non-GAAP basis; reconciliations to closest GAAP equivalent provided

**FY11 guidance as of Analyst Meeting on March 3, 2011

AGILENT OPERATING MODEL*

	FY11 Guidance** (Mid-Point)	-1 σ	MOST PROBABLE***	+1 σ
Organic Revenue Growth %	12%	4%	8%	12%
OM %	18%	18%	20%	21%
YoY OM Incremental %		20%	36%	43%
ROIC %	22%	23%	25%	27%

*Presented on a non-GAAP basis

**FY11 guidance as of Analyst Meeting on March 3, 2011

***Not company guidance

Continue to focus on four point strategy

- **Market reach and customer trust**
 - Sales, service, and support reach into over 100 countries
 - #1 customer loyalty ranking in every major product category*
 - 42% of employees based in Asia
- **Technology leadership**
 - 10% Revenue invested in R&D and over 2500 employees
 - Highest performing Oscilloscopes, Sources & Signal Analyzers, Network Analyzers, Liquid and Gas Chromatographs, and Mass Spectrometers
- **Scale**
 - Among the lowest instrument cost of sales in the industry
 - Purchasing power and infrastructure leverage
- **Team**
 - Top quartile employee satisfaction
 - Well below average industry turnover

All built on Agilent's operating model

*Source: Lieberman Research Worldwide



AGILENT TECHNOLOGIES

BARCLAYS CAPITAL 2011 GLOBAL HEALTHCARE CONFERENCE

HELEN STIMSON

VICE PRESIDENT & GENERAL MANAGER

CHEMISTRIES AND SUPPLIES


CHEMICAL ANALYSIS GROUP

LARGE AND DIVERSIFIED ADDRESSABLE MARKET

Market segmentation*

Markets	Size (\$B)*	Growth*
Life Sciences	\$19	5% - 7%
Chemical Analysis	10	5% - 6%
Electronic Measurement	12	4% - 5%
Total Market	\$41	5% - 7%

Agilent revenue diversification (LTM**)



Growth Drivers

- Operational Surveillance
- High Speed Data Transport
- Communications 3G/4G
- Modular Instruments
- Nanotechnology
- Food Safety
- Environment
- New Energies
- Therapeutic Markets

Emerging Markets

- Brazil
- Russia
- India
- China
- and others



\$41B market opportunity across a diversified customer base

*Company estimates

**Represents last four quarters of revenue: Q2 FY10 – Q1 FY11

LIFE SCIENCES MARKET OVERVIEW

Pharma/Biotech

(For Profit)



14% of Agilent revenue

Academic and Government

(Not-For-Profit)



7% of Agilent revenue

Market Size: \$19B

Growth: 5-7%

Growth Drivers

- Academic and government investment
- Life Science applications – “omics”
- Growth in generics, developing economies
- Therapeutic target conversion to New Biological Entities
- UHPLC acceleration of Pharma LC replacement cycle

(1) Market size and growth data per Company estimates

(2) Percentages of Agilent revenue based on last four quarters of revenue: Q2 FY10 – Q1 FY11

Accelerate workflows through technology leadership

1200 Infinity Liquid Chromatography Series

- Includes new Agilent 1220 Infinity LC, new Agilent 1260 Infinity LC and enhanced Agilent 1290 Infinity LC
- 1290 offers industry's largest power range (0-1200 bar, up to 5ml/min) for highest speed and resolution and 2-80x increased sensitivity
- 1290's power range facilitates ultra-high-pressure LC method development



6490 Triple Quad LC/MS System

- Breakthrough tenfold sensitivity increase enables new applications
- Revolutionary iFunnel Platform Technology atmospheric pressure ion sampling drives sensitivity and provides high reliability

SureSelect™ XT Target Enrichment System

- First fully customizable liquid genome partitioning/enrichment system
- Automates and enhances nucleic acid sequencing experiment when used in front of “next-generation” sequencing technologies



NMR

Channel – Immediate Impact

- Rapidly staffing global service and support
- Solid orders growth, long cycle products mean future revenue

Technology – Results Primarily in 2012

- New console ships from Penang - Q2 2011
- U.S. R&D teams relocated to Agilent sites - Q2 2011
- Project started to build world's largest NMR Magnet

Operations – Momentum Builds Over Cycle

- Global Procurement teams engaged
- Manufacturing relocation in progress
- Business transformation – Agilent incrementals

Expected NMR Cost of Sales improvement of 10ppt over 4 years




Grow Market Share

- Deliver leading-edge application solutions customers demand
- Drive emerging application trends
- Leverage strong global presence to expand in developing geographies



Strengthen Technology Base

- Develop breakthrough products and technologies
- Lead new technology restatement and market creation
- Excel in customer service and support



Leverage Agilent's Breadth and Scale

- Incorporate leading-edge electronics across instrumentation
- Drive Cost of Sales improvement via Agilent's geographic procurement strength
- Enable scalable and sustainable growth by leveraging Agilent's global manufacturing footprint



CHEMICAL ANALYSIS MARKET OVERVIEW

Chemical &
Energy



12% of Agilent
revenue

Environmental



8% of Agilent
revenue

Food



6% of Agilent
revenue

Forensics &
Drug



2% of Agilent
revenue

Market Size: \$10B
Growth: 5-6%

Growth Drivers

- China, Emerging Markets
- Food Safety & Environmental Regulations
- Research Funding
- Replacement Market

(1) Market size and growth data per Company estimates

(2) Percentages of Agilent revenue based on last four quarters of revenue: Q2 FY10 – Q1 FY11

CAG ADVANTAGE: PORTFOLIO TRANSFORMATION

Expand Chemistries and Supplies offering



MS Analyzed Vials



GC Columns



HPLC Columns



Consumables



Solid Phase Extraction



Polymeric Columns

Expand leadership in Atomic and Molecular Spectroscopy



Exoscan



ICP-MS with MassHunter Workstation



AA and OES



UV-Vis

Driven by
Technology
Leadership

Leverage unique position of instrument and vacuum leadership



FRG-720
Full Range Gauge



MS40+ Large Capacity
Rotary Vane



Turbo 850

Broaden GC-MS portfolio and sample prep solutions



Micro GC



Transportable
GC/MSD



Sample Prep
Workbench



GC-MS
Triple Quad



Headspace
Sampler



Ion Trap

CAG VARIAN COST SYNERGY CAPTURE

Leverage Agilent Asia supply chain.

Shift manufacturing and material sourcing to lower-cost countries; leverage existing capability.

Reduce vertical integration. Outsource internal sub-assemblies.

Streamline distribution and commercial centers. Eliminate redundancy, gain efficiency and new scale.

Re-engineer products. New product designs and components, coupled with engineering heritage.



Agilent Penang campus

Expected Cost of Sales improvement of 10ppt over 4 years

CHEMICAL ANALYSIS: OUR WINNING FORMULA

Focus on Growth Geographies. Strong foundation, Agilent core competency.

Leading Technology. Innovative products, emerging applications, investment model.

Superior Customer Experience. Proven Sales and Services model.

M&A Synergy-Capture Capabilities. Varian revenue and margin.

Operational Excellence. Manufacturing and Logistics model.



SUMMARY

1. Revenue momentum is expected to continue into 2011
2. Agilent is well positioned in each of our three businesses
3. Varian integration is going well
4. Drive the center of the operating model to 20% operating margin* and 25% ROIC*
5. Uses of cash:
 - Create value organically and through acquisition
 - Maintain share count to offset dilutive impact of stock compensation programs
 - Strengthen investment grade ratings

*Presented on a non-GAAP basis



APPENDIX

AGILENT TECHNOLOGIES, INC.
ELECTRONIC MEASUREMENT SEGMENT

(Unaudited)

(In millions, except margin data)	FY 2011				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 797				\$ 797
Net revenue	\$ 771				\$ 771
Gross margin %	58.1%				58.1%
Income from operations	\$ 157				\$ 157
Operating margin %	20.3%				20.3%
	FY 2010				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 642	\$ 784	\$ 750	\$ 818	\$ 2,994
Net revenue	\$ 629	\$ 699	\$ 692	\$ 764	\$ 2,784
Gross margin %	57.3%	58.8%	58.8%	58.7%	58.4%
Income from operations	\$ 58	\$ 100	\$ 127	\$ 153	\$ 438
Operating margin %	9.3%	14.2%	18.3%	20.0%	15.7%

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to the amortization of intangibles, the impact of restructuring charges, the acquisition of Varian, Inc., and the sale of our businesses.

In general, recorded orders represent firm purchase commitments from our customers with established terms and conditions for products and services that will be delivered within six months.

Historical amounts have been reclassified to conform with current period presentation.

AGILENT TECHNOLOGIES, INC.
CHEMICAL ANALYSIS SEGMENT

(Unaudited)

(In millions, except margin data)	FY 2011				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 388				\$ 388
Net revenue	\$ 349				\$ 349
Gross margin %	51.1%				51.1%
Income from operations	\$ 65				\$ 65
Operating margin %	18.7%				18.7%
	FY 2010				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 242	\$ 231	\$ 350	\$ 401	\$ 1,224
Net revenue	\$ 244	\$ 238	\$ 329	\$ 389	\$ 1,200
Gross margin %	55.1%	54.5%	52.7%	52.5%	53.5%
Income from operations	\$ 67	\$ 57	\$ 69	\$ 86	\$ 279
Operating margin %	27.5%	23.9%	21.0%	22.1%	23.3%

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to the amortization of intangibles, the impact of restructuring charges, the acquisition of Varian, Inc., and the sale of our businesses.

In general, recorded orders represent firm purchase commitments from our customers with established terms and conditions for products and services that will be delivered within six months.

Historical amounts have been reclassified to conform with current period presentation.

AGILENT TECHNOLOGIES, INC.
LIFE SCIENCES SEGMENT

(Unaudited)

(In millions, except margin data)	FY 2011				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 442				\$ 442
Net revenue	\$ 404				\$ 404
Gross margin %	53.3%				53.3%
Income from operations	\$ 48				\$ 48
Operating margin %	11.8%				11.8%
	FY 2010				
	Q1	Q2	Q3	Q4	Total
Orders	\$ 336	\$ 331	\$ 391	\$ 468	\$ 1,526
Net revenue	\$ 340	\$ 334	\$ 374	\$ 431	\$ 1,479
Gross margin %	54.4%	55.0%	53.8%	51.2%	53.5%
Income from operations	\$ 55	\$ 48	\$ 56	\$ 62	\$ 221
Operating margin %	16.3%	14.2%	14.9%	14.5%	15.0%

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to the amortization of intangibles, the impact of restructuring charges, the acquisition of Varian, Inc., and the sale of our businesses.

In general, recorded orders represent firm purchase commitments from our customers with established terms and conditions for products and services that will be delivered within six months.

Historical amounts have been reclassified to conform with current period presentation.

AGILENT TECHNOLOGIES, INC
RECONCILIATION FROM GAAP TO NON-GAAP

TWELVE MONTHS ENDED October 31, 2010
(Unaudited)

		Non-GAAP Adjustments															
		GAAP	Restructuring and Other Related Costs - FY 2009 Plan	Asset Impairments	Intangible Amortization	Transformational Restructuring	Litigation Settlement	Business Divestitures	Varian Acquisition & Integration Costs	Varian Acquisition Related Fair Value Adjustments	Acceleration of Share-Based Compensation Expense Related to Workforce Reduction	Tax Sharing Settlement	Other	Adjustment for Taxes	Non-GAAP		
Orders	Change Year Over Year	28%	\$ 5,744	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,744	28% Change Year Over Year
Net revenue	Change Year Over Year	21%	\$ 5,444	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 19	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,463	22% Change Year Over Year
Costs and expenses:																	
Cost of products and services	Gross Margin	53.8%	2,514	(8)	(5)	(49)	(15)	-	(1)	(32)	-	-	(1)	-	2,403	56.0% Gross Margin	
Research and development	As a % of Revenue	11.2%	612	(3)	-	(7)	(7)	-	-	-	-	-	(1)	-	601	11.0% As a % of Revenue	
Selling, general and administrative	As a % of Revenue	32.2%	1,752	(53)	(14)	(28)	(17)	-	(13)	(101)	-	(1)	-	(2)	1,523	27.9% As a % of Revenue	
Total costs and expenses			4,878	(64)	(19)	(77)	(39)	-	(13)	(102)	(32)	(1)	-	(4)	4,527		
Income from operations	Operating Margin	10.4%	566	64	19	77	39	-	13	102	51	1	-	4	936	17.1% Operating Margin	
Other income (expense), net			126	-	-	-	(8)	(129)	-	-	-	(54)	1	-	(64)		
Income before taxes			692	64	19	77	39	(8)	(116)	102	51	1	(54)	5	872		
Provision for taxes	Tax rate (incl. Valuation Allowance)	1%	8	-	-	-	-	-	-	-	-	-	-	158	166	Tax rate (incl. Valuation Allowance)	
Net income	Net Margin	12.6%	\$ 684	\$ 64	\$ 19	\$ 77	\$ 39	\$ (8)	\$ (116)	\$ 102	\$ 51	\$ 1	\$ (54)	\$ 5	\$ (158)	\$ 706	12.9% Net Margin
Net income per share - Basic and Diluted:																	
	Basic		\$ 1.97	\$ 0.18	\$ 0.05	\$ 0.22	\$ 0.11	\$ (0.02)	\$ (0.33)	\$ 0.29	\$ 0.15	\$ -	\$ (0.16)	\$ 0.01	\$ (0.44)	\$ 2.03	
	Diluted		\$ 1.94	\$ 0.18	\$ 0.05	\$ 0.22	\$ 0.11	\$ (0.02)	\$ (0.33)	\$ 0.29	\$ 0.14	\$ -	\$ (0.15)	\$ 0.01	\$ (0.44)	\$ 2.00	
Weighted average shares used in computing net income per share:																	
	Basic		347	347	347	347	347	347	347	347	347	347	347	347	347	347	
	Diluted		353	353	353	353	353	353	353	353	353	353	353	353	353	353	

The preliminary reconciliation from GAAP to Non-GAAP net income is estimated based on our current information.

AGILENT TECHNOLOGIES, INC
RECONCILIATION FROM GAAP TO NON-GAAP

THREE MONTHS ENDED January 31, 2011
(Unaudited)

		Non-GAAP Adjustments										
		GAAP	Restructuring and Other Related Costs	Intangible Amortization	Transformation Initiatives	Varian Acquisition & Integration Costs	Varian Acquisition Related Fair Value Adjustments	Other	Adjustment for Taxes	Non-GAAP		
(In millions, except per share amounts)												
Orders	Change Year Over Year	33%	\$ 1,627	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 1,627	33% Change Year Over Year
Net revenue	Change Year Over Year	25%	\$ 1,519	\$ -	\$ -	\$ -	\$ -	\$ 5	\$ -	\$ -	\$ 1,524	26% Change Year Over Year
Costs and expenses:												
Cost of products and services	Gross Margin	53.7%	703	-	(17)	(4)	(1)	1	1	-	683	55.2% Gross Margin
Research and development	As a % of Revenue	10.5%	159	-	-	(1)	-	-	-	-	158	10.4% As a % of Revenue
Selling, general and administrative	As a % of Revenue	29.4%	446	(2)	(11)	(6)	(14)	-	-	-	413	27.1% As a % of Revenue
Total costs and expenses			1,308	(2)	(28)	(11)	(15)	1	1	-	1,254	
Income from operations	Operating Margin	13.9%	211	2	28	11	15	4	(1)	-	270	17.7% Operating Margin
Other income (expense), net			(13)	-	-	-	-	-	1	-	(12)	
Income before taxes			198	2	28	11	15	4	-	-	258	
Provision (benefit) for taxes	Tax rate (incl. Valuation Allowance)	3%	5	-	-	-	-	-	-	41	46	Tax rate (incl. Valuation Allowance) 18%
Net income	Net Margin	12.7%	\$ 193	\$ 2	\$ 28	\$ 11	\$ 15	\$ 4	\$ -	\$ (41)	\$ 212	13.9% Net Margin

Net income per share - Basic and Diluted:

Basic	\$ 0.56	\$ 0.01	\$ 0.08	\$ 0.03	\$ 0.04	\$ 0.01	\$ -	\$ (0.12)	\$ 0.61
Diluted	\$ 0.54	\$ 0.01	\$ 0.08	\$ 0.03	\$ 0.04	\$ 0.01	\$ -	\$ (0.11)	\$ 0.60

Weighted average shares used in computing net income (loss) per share:

Basic	347	347	347	347	347	347	347	347	347
Diluted	355	355	355	355	355	355	355	355	355

The preliminary reconciliation from GAAP to Non-GAAP net income is estimated based on our current information.

AGILENT TECHNOLOGIES, INC.
REVENUE RECONCILIATION
(In millions)
(Unaudited)
PRELIMINARY

	<u>Q1'11</u>	<u>Q1'10</u>	<u>Percent Inc/(Dec)</u>	<u>FY'10</u>	<u>FY'09</u>	<u>Percent Inc/(Dec)</u>
GAAP Revenue	\$ 1,519	\$ 1,213		\$ 5,444	\$ 4,481	
Varian acquisition fair value adjustments	5	-		19	-	
Non-GAAP Revenue	<u>\$ 1,524</u>	<u>\$ 1,213</u>		<u>\$ 5,463</u>	<u>\$ 4,481</u>	
Less revenue from acquisition and divestitures included in segment results	(134)	(47)		(423)	(240)	
Non-GAAP Revenue, adjusted	<u>\$ 1,390</u>	<u>\$ 1,166</u>	19%	<u>\$ 5,040</u>	<u>\$ 4,241</u>	19%

Revenues, excluding the impact of the Varian acquisition and recent divestitures, are a non-GAAP measure and are defined to exclude the fair value adjustment to acquisition related deferred revenue balances for the Varian acquisition and exclude the impacts of the Varian acquisition and the divestitures of our Network Systems and Hycor businesses.

Management believes that this measure provides useful information to investors by reflecting an additional way of viewing aspects of Agilent's operations that, when reconciled to the corresponding GAAP measures, help our investors to better identify underlying growth trends in our business and facilitate easier comparisons of our revenue performance with prior and future periods and to our peers. We excluded the effect of the Varian acquisition and recent divestitures because the nature, size and number of these can vary dramatically from period to period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.

AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF ROIC
(IN MILLIONS)
PRELIMINARY

Numerator:	Agilent		Agilent	
	Q1'11	Q1'10	FY10	FY09
Adjusted income from operations	\$ 270	\$ 181	\$ 936	\$ 393
Less:				
Taxes and Other (income)/expense	43	30	164	67
Agilent return ^(a)	227	151	\$ 772	\$ 326
Agilent return annualized	\$ 908	\$ 604		
Denominator:				
Agilent assets ^(b)	\$ 5,516	\$ 3,934	\$ 5,442	\$ 3,566
Less:				
Net current liabilities ^(c)	1,094	886	\$ 1,251	927
Invested capital	\$ 4,422	\$ 3,048	\$ 4,191	\$ 2,639
Average invested capital	\$ 4,307	\$ 2,844	\$ 3,654	\$ 2,838
ROIC	21%	21%	21%	11%

ROIC QTD calculation:(annualized current quarter segment return)/(average of the two most recent quarter-end balances of Segment Invested Capital)

ROIC YTD calculation : (Agilent annual return)/ (average of the five most recent quarter-end balances of Agilent Invested Capital)

^(a) Agilent return is equal to adjusted net income from continuing operations minus net interest income after tax.

Please see "Adjusted Net Income and diluted EPS Reconciliations" for a reconciliation of adjusted net income from continuing operations to GAAP income from continuing operations.

^(b) Assets consist of inventory, accounts receivable, property plant and equipment, gross goodwill and other intangibles, deferred taxes and allocated corporate assets.

^(c) Includes accounts payable, employee compensation and benefits, other accrued liabilities and allocated corporate liabilities.

Historical amounts were reclassified to conform with current period presentation.

Return on invested capital (ROIC) is a non-GAAP measure that management believes provides useful supplemental information for management and the investor. ROIC is a tool by which we track how much value we are creating for our shareholders. Management uses ROIC as a performance measure for our businesses, and our senior managers' compensation is linked to ROIC improvements as well as other performance criteria. We believe that ROIC provides our management with a means to analyze and improve their business, measuring segment profitability in relation to net asset investments. We acknowledge that ROIC may not be calculated the same way by every company. We compensate for this limitation by monitoring and providing to the reader a full GAAP income statement and balance sheet.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary reconciliation of ROIC is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF REVENUE BY REGION
(IN MILLIONS)
PRELIMINARY**

	<u>Q1'11</u>	<u>Q1'10</u>	<u>Percent Inc/(Dec)</u>
GAAP			
Americas	\$ 548	\$ 437	25%
Europe	405	339	20%
Asia Pacific	566	437	30%
Revenue	<u>\$ 1,519</u>	<u>\$ 1,213</u>	25%
Non-GAAP			
Americas	\$ 505	\$ 407	24%
Europe	362	327	11%
Asia Pacific	523	432	21%
Organic revenue, adjusted for acquisition & divestitures	<u>\$ 1,390</u>	<u>\$ 1,166</u>	19%

The preliminary reconciliation of revenue by region is based on our current information.